A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors

Sharad Sharma, Vivek Abhyankar, R Burgess, J. Infante(Sarah Cannon), R. C. Trowbridge, Jamal Tarazi(Pfizer (United States)), Sophie Y Kim(Pfizer (United States)), Michael A. Tortorici(Pfizer (United States)), Y. Chen(Pfizer (United States)), Robert Leon Robles
Annals of Oncology
November 26, 2009
10.1093/annonc/mdp489
Cited by 56Open Access
Full Text

Abstract

Related Papers

Clinical Pharmacology of 5-Fluorouracil
Robert B. Diasio, Barry Harris|Clinical Pharmacokinetics|1989|962
Phase I Safety and Pharmacokinetic Study of Recombinant Human Anti-Vascular Endothelial Growth Factor in Patients With Advanced Cancer
Michael S. Gordon, Kim Margolin, Moshe Talpaz et al.|Journal of Clinical Oncology|2001|919
Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3
Dana D. Hu‐Lowe, Helen Y. Zou, Maren L. Grazzini et al.|Clinical Cancer Research|2008|628
Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study
Ezra E.W. Cohen, Lee S. Rosen, Everett E. Vokes et al.|Journal of Clinical Oncology|2008|622
UDP-glucuronosyltransferases and clinical drug-drug interactions
Tony K. L. Kiang, Mary H. H. Ensom, Ting‐Shou Chang|Pharmacology & Therapeutics|2005|546